Yüklüyor......
An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines
Pulmonary fibrosis (PF) is chronic lung disease with only two FDA approved clinically available drugs, with limited safety profile. Inadequate therapy motivated us to explore the effect of vimentin inhibitor Withaferin A, as an anti-fibrotic agent against TGF-β1-induced in vitro fibrotic events and...
Kaydedildi:
| Yayımlandı: | Front Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5874319/ https://ncbi.nlm.nih.gov/pubmed/29623041 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00248 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|